Open Position

 

Lab Facilities

 

Complete CV 

 

Collaborators

Research Areas

Recent News/Events

 Mahato’s Lab website Address:  http://www.utmem.edu/Mahato_Lab

    Center for Cancer Research at UT Website:       http://www.utmem.edu/cancer/

Ram I. Mahato, Ph.D.

Associate Professor(Tenured)
Department of Pharmaceutical Sciences
University of Tennessee Health Science Center
Cancer Research Building

19 South Manassas (Room 224)

Memphis, TN 38103-3308
Tel: (901) 448-6929 (office), 448-6848 (Lab)
Fax: (901) 448-2099
E-mail: rmahato@utmem.edu
http://cop.utmem.edu/rmahato

 

 

EDUCATION AND PROFESSIONAL EXPERIENCE:

Education: Ph.D. in Pharmaceutics and Drug Delivery from the University of Strathclyde, Britain (1989-92), B.S. in Pharmaceutics from China Pharmaceutical University, China. (1985-89), Diploma in Chinese from Beijing Language Institute, China (1984-85), Certificate Level in Science from Tribhuwan University, Nepal (1981-83).

 

Professional Experience:

Assistant Professor, Department of Pharmaceutical Sciences, University of Tennessee Health Science Center (2001-2005), Research Assistant Professor, Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah (1999-2001), Senior Scientist, Gene Delivery Sciences, GeneMedicine, inc. (Valentis, Inc., 1996-99), Research Scholar, Gene Delivery Sciences, Faculty of Pharmaceutical Sciences, Kyoto University, Japan (1994-96), Postdoctoral Fellow, Departments of Chemical Engineering and Ophthalmology, Washington University, St. Louis (1993-1994), Research Associate, Department of Pharmaceutical Sciences, University of Southern California, Los Angeles (1992).  

 

HONORS AND AWARDS:

2006       Nonviral Gene Transfer Vectors Scientific Committee Member, American Society of Gene Therapy; Symposium Chair, Biomaterials for Site-specific Delivery of Oligonucleotides and siRNA, National Biotechnology Conferences (June 18-21, Boston, MA)

2005       Short Course Chair, Pharmaceutical Perspectives of Synthetic and Hybrid Vectors-based Nucleic Acid Therapeutics, 2005 AAPS Annual Meeting and Exposition (Nashville, 2005)

2004       Invited Speaker, Modulation of Gene Expression by Antisense, Antigene and sRNAi, 31st Controlled Release Society (CRS) Annual Meeting (Hawai, 2004); Invited Speaker, Viral Medicine? Never, Pearls of Wisdom, 31st Controlled Release Society (CRS) Annual Meeting (Hawai, 2004);

2003:      Invited Speaker, Challenges of Antisense Oligonucleotide Delivery, 30th Controlled Release Society (CRS) Annual Meeting (Glasgow, UK, 2003); Who’sWho in America (2003)

2002:      Invited Speaker on Functional and Biospecific Polymers for Therapeutic Gene Delivery, AAPS Workshop on Critical Issues in the Design & Applications of Polymeric Biomaterials in Drug Delivery (Arlington, VA, 2002)

               Session Chair, Therapeutic Gene/Oligonucleotide Delivery, 29th CRS Annual Meeting (Seoul, Korea, 2002)

2000       Invited Speaker on Introduction to Gene Therapy at Sunrise School of Pharmacy at the AAPS Annual Meeting (Indianapolis, 2000)

1999       Invited Speaker, Tailor made polymeric gene carriers at the 3rd Congress of Eur Assoc Clin Pharmacol Ther (EACPT) (Jerusalem, Israel, 1999)

1995-96 Goho Foundation Fellowship (Japan) 

1994-95 Uehara Foundations Fellowship (Japan)

1989-92 Cancer Research Campaign PhD Studentship of the United Kingdom

1986       International Student Award by China Pharmaceutical University, China

1984-8    Undergraduate studies supported by the Ministry of Education, Nepal

 

NATIONAL AND INTERNATIONAL SCIENTIFIC REVIEW PANELS:

  1. Clinical & Experimental Therapeutics-3 (CET-3) Panel Meeting, Department of Defense, July 20-22, 2008.

  2. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, May 19-20, 2008.

  3. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, February 4-5, 2008.

  4. Susan G. Komen for the Cure Panel Meeting at Alexandria, VA, January 10-11, 2008.

  5. National Institutes of Health, Special Emphasis Panel on Enzyme Assessment Core, NIDDK, November 15, 2007.

  6. Clinical & Experimental Therapeutics-3 (CET-3) Panel Meeting, Department of Defense, August 15-17, 2007.

  7. Israel Science Foundation, March 2007.

  8. Wellcome Trust, Great Britain, January 2007.

  9. Alberta Heritage Foundation for Medical Research, Canada, December 2006.

  10. National Institutes of Health, Nanoscience and Nanotechnology, Washington D.C., July 2004.

  11. National Institutes of Health, Nanoscience and Nanotechnology (Washington D.C., March 2004

  12. James and Esther King Biomedical Research Program, 2004-Present.

  13. Engineering & Biological Systems (EBS) of Great Britain, April, 2004.

  14. American Institute of Biological Sciences, October-November, 2002.

  15. National Institutes of Health, Gene Therapy Panel, March, 2002.

SERVICE TO PROFESSIONAL ASSOCIATIONS:

Moderator

1.     Site-specific Delivery and Targeting of Nucleic Acids for treating Fibrosis, 2008 National Biotechnology Conference (NBC), Toronto, Canada, June, 2008.

2.     Nanoencapsulation I, 34th Controlled Release Society Annual Meeting, Long Beach, CA, July, 2007.

3.     Session 13: Solutions to Novel Drug Delivery System, 5th Annual Drug Discovery Conference and Expo (IDDST), Shanghai, China, May 27-31, 2007.

4.     Biomaterials for Site-specific Delivery of Oligonucleotides and siRNA; and Emerging Trends in Cell-Based Therapeutics, National Biotechnology Conferences, Boston, MA, June 18-21, 2006.

5.     Delivery, Transport and Transcription, 9th Annual Meeting of American Society of Gene Therapy (ASGT), Baltimore, MD, May 31-June 4, 2006.

6.     Short Course Chair on Pharmaceutical Perspectives of Synthetic and Hybrid Vectors-based Nucleic Acid Therapeutics, AAPS Annual Meeting and Exposition, Nashville, October, 2005.

7.     Delivery of Nucleotide-based Therapeutics, 32nd Controlled Release Society Annual Meeting (Miami, Florida, 2005)

8.     Workshop Chair on Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics, 31st Controlled Release Society (CRS) Annual Meeting, Hawaii, July, 2004.

9.     Challenges for Oligonucleotide Delivery, 30th Controlled Release Society Annual Meeting (Glasgow, Scotland, 2003)

10.  Therapeutic Gene/Oligonucleotide Delivery, 29th CRS Annual Meeting, Seoul, Korea, July, 2002.

 Symposia/Workshop Organizer

1.     CRS 2008 Educational Workshop Review Committee, 35th Controlled Release Society Annual Meeting, New York, NY (Role: Member)

2.     Workshop Chair on Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics, 31st Controlled Release Society (CRS) Annual Meeting, Hawaii, July, 2004 (Role: Organizer)

3.     Round-table on Disposition of Nonviral Gene Delivery Systems and Oligonucleotides. Annual AAPS Meeting, San Francisco, CA, November, 1998 (Role: Co-organizer along with Shankar Musunuri and Uday B. Kompella). 

4.     Member, 2007 CRS/Jorge Heller Journal of Controlled Release Award Committee.

 

EDITORIAL ACTIVITIES:

Editor:                Pharmaceutical Research

Editorial Board: Journal of Drug Targeting

Expert Opinion on Drug Delivery

 

Referee for Journals

Advanced Drug Delivery Reviews, American Journal of Drug Delivery, Antiviral Research, Biomacromolecules,       Biophysical Journal, Chemistry and Physics of Lipids, Clinical Pharmacokinetics, Critical Reviews in Therapeutic Drug Carrier Systems, Diabetologica, Drug Development Industrial Pharmacy, Drug Discovery Today, Expert Opinion on Drug Delivery, European Journal of Pharmaceutical Sciences, European Journal of Pharmaceutics and Biopharmaceutics, Gene Therapy, Human Gene Therapy, International Journal of Pharmaceutics, Journal of Controlled Release, Journal of Drug Targeting, Journal of Electrochemical Society, Journal of Gene Medicine,  Journal of Pharmacology and Experimental Therapeutics, Molecular Pharmaceutics, Molecular Therapy,  Nucleic Acids Research, Pharmaceutical Research,  Proceedings of the National Academy of Sciences, S.T.P. Pharma Sciences.

 

Professional Society Membership

Controlled Release Society, American Association of Pharmaceutical Sciences, American Society of Gene Therapy, American Chemical Society, New York Academy of Science, American Association for the Advancement of Science, Pharmaceutical Society of Japan.  

 

RESEARCH SUPPORT:

ACTIVE:

NIH/R01        DK69968-01A1

Principal Investigator:                Ram I. Mahato, Ph.D.

Growth Factor Gene Delivery to Human Pancreatic Islets

The goal of this project is to develop adenovirus-based growth factor and antiapoptotic gene delivery to human pancreatic islets for treatment of type I diabetes.  

 

NIH 1 R01 EB003922-02                                 03/01/07– 02/28/10                           

Principal Investigator:                               Ram I. Mahato, Ph.D.

Targeted Delivery of TFOs for Treatment of Liver Fibrosis

The major goal of this project is to targeted delivery of a1(I) collagen gene promoter specific triplex forming oligonucleotides (TFOs) to liver fibrogenic cells in fibrotic rats after conjugation with mannose 6-phosphate-bovine serum albumin (M6P-BSA) via a disulfide bond.

NIH/R01  DK64366-01A1        01/01/04-12/31/08

Principal Investigator:   Ramareddy V. Guntaka, Ph.D.

Coinvestigator:              Ram I. Mahato, Ph.D.

A Promoter-Specific TFO Prevents Liver Fibrosis

Fibrosis is due to abnormal accumulation of type I collagen in the interstitial space of various organs. The goal of this project is to use a triplex-forming oligonucleotide as an antigene agent targeting the promoter of a1(I) collagen gene.

 

UT Rheumatic Diseases Research Core Center Grant   9/01/04-9/30/06

Principal Investigator:   Ram I. Mahato, Ph.D.

Targeted Delivery of Oligonucleotides into Hepatic Stellate Cells

The goal of this project is to develop receptor-mediated delivery strategies for oligonucleotides to hepatic stellate cells to inhibit collagen production for treatment of liver fibrosis. 

 

Teaching and Faculty Responsibilities:

·         PHSC111: Physical Pharmacy to PharmD Students

·         PHSC911: Delivery and Biocompatibility of Protein and Nucleic Drugs to Graduate Students

·         Member, Graduate Curriculum  and Faculty Development Committees, University of Tennessee Health Science Center,  Memphis, TN

 

RESEARCH ACTIVITIES/INTERESTS:

These are exciting times in the scientific world.  The public all over the world is fascinated by the spectacular advances in gene therapy, sequencing of the human genome, and stem cell research.  These advances promise to prevent, correct or modulate genetic and acquired diseases, which use genes to produce therapeutic proteins or inhibit aberrant protein production.  The launching of the human proteome project has turned functional genomics and proteomics into powerful bullworks, which will give us an integrated scenario of turning nucleic acids into therapeutics.  The development of effective nucleic acid therapeutics demands teamwork among scientists with expertise in molecular and cell biology, biochemistry, biophysics, polymer chemistry, colloid science, pharmaceutics, and medicine. In the last decade, significant progress has been made in the use of nucleic acids, such as plasmid DNA, antisense oligonucleotides, siRNA, ribozymes, peptide nucleic acids (PNA) and aptamer nucleic acids for nucleic acid therapy. 

Our research involves in the following distinct arena: (i) Delivery of Oligonucleotides, siRNA and shRNA for Treatment of Hepatitis, Liver Fibrosis, Diabetes; Prostate Cancer and Hepatocellular Carcinoma (ii) Design and Synthesis of Novel Polymers, Lipopeptides, Lipopolymers and Cationic Lipids for Nucleic Acid Delivery, (iii) Design and Construction of Novel Plasmid and Adenovirus-based Gene and shRNA Expression Systems, (iv) Formulation and In Vitro Characterization of Nucleic Acid Delivery Systems to various Disease Targets, (v) Mechanisms of Cellular Uptake and Intracellular Trafficking of Nucleic Acid Drugs, (vi) Therapeutic Gene Delivery to Pancreatic Human Islets for the Treatment of Diabetes, (vii) Targeted Delivery of Triplex-Forming Oligonucleotides (TFO) and siRNA for the Treatment of Hepatitis and Fibrosis, and (viii) Hydrophobization of Protein Drugs for Oral Delivery. We attempt to understand the genesis of structure-synthesis-function interrelationships. How the components of a viable gene expression system would influence the disease state by controlling gene regulation, transcription, translation and replication are also the central theme of our research. 

 

BOOK EDITOR:

  1. Mahato RI. Pharmaceutical Dosage Forms and Drug Delivery(2007), CRC Press, Inc., FL

  2. Mahato RI (Ed) Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids (2005), CRC Press, Inc., FL

  3.  Mahato RI and Kim SW (Eds) Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics (July 2002), Francis and Taylor, London.

 

JOURNAL THEME ISSUE EDITOR:

  1.  Ye Z and Mahato RI (Eds) Special Issue on the Emerging Trends in Cell-based Therapeutics (2008) Adv Drug Del Rev 60: 89-90

  2. Mahato RI (Ed) Special Issues on Gene Delivery and Targeting (1999 and 2000) Journal of Drug Targeting 7: 241-313; 7: 407-470; and 8: 1-66. 

  3. Mahato RI (Ed) Theme Issue on Challenges of Turning Nucleic Acids into Therapeutics (2000) Adv. Drug Del. Rev. 44 (2-3): 79-207. 

 

 EDITORIALS & COMMENTARIES/BOOK REVIEWS:

  1. Ye Z and Mahato RI (2008) Role of nanomedicines in cell-based therapeutics. Nanomedicines 3: 5-8.  

  2. Mahato RI and Narang AS (2005) Need of closer alliances for turning nucleic acids into nanomedicines. CRS Newsletter 22(1): 22, 25, 31.

  3. Book Review: A. Rolland and S.M. Sullivan, Editors, Pharmaceutical Gene Delivery Systems, Marcel Dekker, New York (2004) (424 pp.), J Control Rel 104: 233-234.

  4. Mahato RI (2000) Challenges of turning nucleic acids into therapeutics. Adv Drug Deliv Rev 44: 79-80.

  5. Mahato RI (1999): Editorial: Plasmid-based gene therapy: Opportunities and challenges knock the millennium. J Drug Target 7: 241-244.

  6. Mahato RI, Fons MP and A Rolland (1998) Nonviral gene therapy: From Bench to the Clinic. CRS Newsletter 15: 9-11.

 

 PATENTS & INVENTION DISCLOSURES: 

  1. RI Mahato, AO Gaber, AS Narang, D Fraga and M Kotb (2003) Vascular endothelial growth factor gene delivery to human islets for neoangiogenesis after transplantation.  Filed for patent by the University of Tennessee Health Science Center, Memphis

  2. RI Mahato, A Maheshwari and SW Kim (2005) Soluble steroidal peptides for nucleic acid delivery. US Patent# 6,875,611 and  7,320,890 B2

  3. RI Mahato, SO Han and DY Furgeson (2004) Cationic lipopolymer as biocompatible gene delivery agent. US Patent# 6,696,038.

 

RESEARCH PAPERS:

  1. Li F and Mahato RI (2008) iNOS gene silencing prevents inflammtory cytokine induced beta cell apoptosis. Mol Pharm 5: 407-417.

  2. Chen Y and Mahato RI (2008) siRNA Pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection. J Drug Target 16:140-148.

  3. Zhu L, Ye Z, Cheng K, Miller DD and Mahato RI (2008) Site-specific delivery of oligonucleotides to hepatocytes after systemic administration. Bioconjugate Chem 19:290-8.

  4. Ye Z, Guntaka RV and Mahato RI (2007) Sequence-specific triple helix formation with genomic DNA. Biochemistry 46: 11240-11252.

  5. De Paula D, Bentley MV and Mahato RI (2007) Effect of iNOS and NF-kB gene silencing on β-cell survival and function. J Drug Target 15: 358-369.

  6. Jia X, Cheng K and Mahato RI (2007) Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist for improved human islet survival and function. Molecular Pharmaceutics 4: 199-207.

  7. Narang AS, Sabek O, Gaber AO, and Mahato RI (2006) Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function. Pharm Res 23: 1970-1982.

  8. Ye Z, Cheng K, Guntaka RV and Mahato RI (2006) Receptor-mediated Hepatic Uptake of M6P-BSA-conjugated Triplex Forming Oligonucleotides in Rats. Bioconjugate Chem 17: 823-830.

  9. Cheng K, Ye Z, Guntaka RV and Mahato RI (2006) Enhanced hepatic uptake and bioactivity of type a1(I) collagen gene promoter specific triplex forming oligonucleotides after conjugation with cholesterol. J Pharmacol Exp Ther 317: 797-805.

  10. Cheng K, Ye Z, Guntaka RV and Mahato RI (2005) Biodistribution and Hepatic Uptake of Triplex Forming Oligonucleotides Against Type ?1(I) Collagen Gene Promoter in Normal and Fibrotic Rats. Molecular Pharmaceutics 2: 206-217.

  11. Ye Z, Cheng K, Guntaka RV and Mahato RI (2005) Targeted delivery of triplex forming oligonucleotides to hepatic stellate cells. Biochemistry 44: 4466-4476.

  12. Narang AS, Thoma L, Miller DD, Mahato RI (2005) Cationic lipids with increased DNA binding affinity for nonviral gene transfer in dividing and nondividing cells. Bioconjug Chem 16: 156-168.

  13. Cheng K, Fraga D, Kotb M, Gaber AO, Guntaka RV and Mahato RI  (2004) Adenovirus-based vascular endothelial growth factor gene delivery to human islets. Gene Ther11: 1105-1116.     

  14. Narang AS, Cheng K, Henry J, Zhang C, Sabek O, Fraga D, Kotb M, Gaber AO and Mahato RI (2004)  Vascular endothelial growth factor gene delivery to human islets for neoangiogenesis after transplantation.  Pharm Res. 21: 15-25.

  15. Mahato RI, Henry J, Narang AS, Sabek O, Fraga D, Kotb and Gaber AO (2003) Cationic lipid and polymer-based gene delivery to human pancreatic islets.  Mol. Ther. 7: 89-100.

  16. Wang D-A, Narang AS, Kotb M, Gaber OA, Miller DD, Kim SW and Mahato RI (2002) Novel branched poly(ethylenimine)-cholesterol water soluble lipopolymers for gene delivery. Biomacromolecules 3: 1197-1207.

  17. Maheshwari A, Mahato RI and Kim SW (2002) Biodegradable polymer-based interleukin-12 gene delivery: Role of induced cytokines, tumor infiltrating cells and nitric oxide in anti-tumor activity.  Gene Ther 9: 1075-1084.

  18. Furgeson DY, Cohen RN, Mahato RI and Kim SW (2002) Design, synthesis and characterization of novel lipoparticulates for systemic gene delivery.  Pharm Res 19: 382-390.

  19. Benns JM, Mahato RI and Kim SW (2002) Optimization factors influencing the transfection efficiency of folate-PEG-folate-graft-polyethylimine.   J Control Release 79: 255-269. 

  20. Benns JM, Maheshwari A, Furgeson DY, Mahato RI and Kim SW (2001) Folate-PEG-Folate-graft-polyethylenimine-based gene delivery.  J Drug Target. 9: 123-139. 

  21. Mahato RI, Lee M, Han S-O, Maheshwari A and Kim SW (2001) Intratumoral delivery of p2CMVmIL-12 using water soluble lipopolymers.  Mol Ther 4: 130-138.  

  22. Han S-O, Mahato RI and Kim SW (2001) Synthesis and characterization of water-soluble lipopolymer for gene delivery.  Bioconjug Chem 12: 337-345. 

  23. Maheshwari A, Mahato RI, McGregor J, Han S-O, Samlowski WE, Park J-S and Kim SW (2000) Soluble biodegradable polymer-based cytokine gene delivery for cancer treatment.  Mol Ther 2: 121-130. 

  24. Benns JM, Choi J-S, Mahato RI, Park J-S and Kim SW (2000) pH sensitive cationic polymer gene delivery vehicle: N-Ac-poly(L-histidine)-graft-poly(L-lysine) comb shaped polymer.  Bioconjug Chem 11: 637-645.

  25. Nomura T, Yamada T, Mahato RI, Watanabe Y, Takakura Y and Hashida M (1999) Gene expression and antitumor effects following direct interferon-g gene transfer with naked plasmid DNA and DC-Chol liposome complexes in mice.  Gene Ther 6: 121-129. 

  26. Mahato RI, Anwer K, Tagliaferri F, Meaney C, Leonard P, Chen W, French M, Wadhwa MS and Rolland A (1998) Biodistribution and gene expression of plasmid/lipid complexes after systemic administration in mice.  Hum Gene Ther 9: 2083-2099. 

  27. Takagi T, Hashiguchi M, Mahato RI, Tokuda H, Takakura Y and Hashida M (1998) Involvement of specific mechanism in plasmid DNA uptake by mouse peritoneal macrophages.  Biochem. Biophys. Res. Commun. 245: 729-733.  

  28. Mahato RI, Takemura S, Takakura Y and Hashida M (1997) Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine). Biochem Pharmacol 53: 887-895. 

  29. Takakura Y, Mahato RI, Yoshida M, Kanamaru T and Hashida M (1996) Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system. Antisense Res Develop 6: 177-183. 

  30. Sawai K, Mahato RI, Oka Y, Takakura Y and Hashida M (1996) Disposition of oligonucleotides in the isolated perfused rat kidney: Involvement of scavenger receptors in their renal uptake. J Pharmaco. Exp Ther 279: 284-290. 

  31. Hashida M, Mahato RI, Kawabata K, Sawai K, Nishikawa M and Takakura Y (1996) Pharmacokinetics of proteins, oligonucleotides, and genes.  J Contr Rel 41: 91-97. 

  32. Yoshida M, Mahato RI, Kawabata K, Takakura Y and Hashida M (1996) Disposition characteristics of plasmid DNA in the single-pass rat liver perfusion systems. Pharm Res 13: 597-601.

  33. Mahato RI, Kawabata K, Nomura T, Takakura Y and Hashida M (1995) Physicochemical and pharmacokinetic characteristics of DNA/cationic liposomes complexes. J Pharm Sci 84: 1267-1271. 

  34. Mahato RI, Kawabata K, Takakura Y and Hashida M (1995) In vivo disposition of plasmid DNA complexed with cationic liposomes. J Drug Target 3: 149.

  35. Mahato RI, Halbert GW, Willmott N and Vezin WR (1994) Micron-sized biodegradable microspheres: Characterization and preparative techniques. J Nep Pharm Assoc 18: 1-16. 

BOOK CHAPTERS

  1. Cheng K and Mahato RI (2006) Biopharmaceutical Challenges: Pulmonary Delivery of Proteins and Peptides. In: Meibohm B (ed) Pharmacokinetics and Pharmacodynamics of Biotech Drugs, Wiley-VCH Verlag GmbH & Co, Weinheim, p. 209-242.

  2. Mahato RI, Ye Z and Kim WS (2006) Water soluble lipopolymers and lipopeptides for nucleic acid delivery. In: Friedmann T and Rossi J (eds) Gene Transfer: Delivery and expression of DNA and RNA, A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, p. 501-506.

  3. Mahato RI and Kim SW (2005) Water soluble lipopolymers for gene delivery. In Amiji MM (ed) Polymeric Drug Delivery:Principles and Applications, CRC Press, Boca Raton, FL, p 175-186.

  4. Mahato RI, Ye Z and Guntaka RV (2005) Antisense and Antigene Oligonucleotides: Structure, Stability and Delivery. In Mahato RI (ed) Biomaterials for Delivery and Targeting of Protein and Nucleic acid Drugs, CRC Press, Boca Raton, FL

  5. Mahato RI (2003) Pharmaceutical delivery systems and dosage forms. In Gourley D and Eoff J (eds) APhA’s Complete Review for Pharmacy, Castle Connolly Publishers, New York (2004)

  6. Mahato RI and Tomlison E (2001) Plasmid-based gene therapy.  In: AM Hillery, AW Lloyd and J Swarbrick (eds) Drug Delivery and Targeting: For Pharmacists and Pharmaceutical Scientists, Taylor & Francis, London, pp. 372-397. 

  7. Mahato RI,  Furgeson DY, Maheshwari A,  Han SO and  Kim SW (2000) Polymeric gene delivery for cancer treatment.  In: K.D. Park, I.C. Kwon, N. Yui, S.Y. Jeong and K. Park (eds) Biomaterials and Drug Deliver towards New Millennium, Han Rim Won Publishing Co., Seoul, Korea, pp. 249-280.  

  8.  Takakura Y, Mahato RI, Nomura T, Sawai K, Yoshida M, Kanamaru T and Hashida M (1995) Development of delivery systems for antisense oligonucleotides. In: Ogata N, Kim SW, Feijen J and Okano T (eds) Advanced Biomaterials in Biomedical Engineering and Drug Delivery Systems, Springer,  New